HRS-5632 vs Kylo-11
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: Lipoprotein(a) · full Atherosclerotic Cardiovascular Disease pipeline
HRS-5632
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06732154 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled study, which is a sound design, but the primary measure is adverse-event and safety monitoring rather than a lipid or cardiovascular outcome, and no results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "The percentage of all reported adverse events, serious adverse events and treatment-related adverse events, serious adverse events.". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: April 2027 · NCT07185776 (registry estimate)
No aligned efficacy figure on record for this race.
Kylo-11
Developed by Sino Biopharmaceutical and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HRS-5632 | Kylo-11 |
|---|---|---|
| LDL-C, % change | —Not reported | —Not reported |
| Non-HDL-C, % change | —Not reported | —Not reported |
| ApoB, % change | —Not reported | —Not reported |
| Lp(a), % change | —Not reported | —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
LDL-C, % change
- HRS-5632
- —Not reported
- Kylo-11
- —Not reported
Non-HDL-C, % change
- HRS-5632
- —Not reported
- Kylo-11
- —Not reported
ApoB, % change
- HRS-5632
- —Not reported
- Kylo-11
- —Not reported
Lp(a), % change
- HRS-5632
- —Not reported
- Kylo-11
- —Not reported
3-point MACE (% with event)
- HRS-5632
- —Not reported
- Kylo-11
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HRS-5632: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Kylo-11: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-5632's landscape · Kylo-11's landscape